Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of XNW27011 in locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
CTR20252730Phase 3Active
- Sponsor
- Sinovent
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ASP546C in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sinovent. Started Aug 2025; status: active.
02
Drugs
ASP546C
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20252730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252730.